"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 32 | 17 | 49 |
| 1996 | 57 | 19 | 76 |
| 1997 | 60 | 22 | 82 |
| 1998 | 67 | 24 | 91 |
| 1999 | 77 | 27 | 104 |
| 2000 | 90 | 42 | 132 |
| 2001 | 94 | 43 | 137 |
| 2002 | 128 | 60 | 188 |
| 2003 | 142 | 60 | 202 |
| 2004 | 152 | 71 | 223 |
| 2005 | 152 | 62 | 214 |
| 2006 | 169 | 96 | 265 |
| 2007 | 195 | 111 | 306 |
| 2008 | 199 | 104 | 303 |
| 2009 | 199 | 120 | 319 |
| 2010 | 244 | 127 | 371 |
| 2011 | 255 | 142 | 397 |
| 2012 | 249 | 110 | 359 |
| 2013 | 238 | 119 | 357 |
| 2014 | 254 | 99 | 353 |
| 2015 | 295 | 118 | 413 |
| 2016 | 251 | 123 | 374 |
| 2017 | 228 | 99 | 327 |
| 2018 | 197 | 82 | 279 |
| 2019 | 159 | 76 | 235 |
| 2020 | 158 | 58 | 216 |
| 2021 | 175 | 55 | 230 |
| 2022 | 118 | 10 | 128 |
| 2023 | 130 | 6 | 136 |
| 2024 | 45 | 67 | 112 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study. Blood Adv. 2025 Jan 14; 9(1):66-77.
-
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood Cancer Discov. 2025 Jan 08; 6(1):23-37.
-
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO). J Natl Cancer Inst. 2025 Jan 01; 117(1):9-19.
-
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025 Jan 01; 110(1):78-91.
-
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 01; 110(1):92-102.
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 Jan 09; 68(1):81-94.
-
Pharmacologic Blockade of a Pioneer Transcription Factor. Cancer Res. 2024 Dec 16; 84(24):4124-4125.
-
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V. JCO Precis Oncol. 2024 Dec; 8:e2400514.
-
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia. Cells. 2024 Nov 20; 13(22).
-
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations. Expert Rev Hematol. 2024 Dec; 17(12):935-946.